A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination ...

ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to ...

Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of ...

Furthermore, the safety and tolerability of bempedoic acid were consistent with findings ... Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...

Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of ...

today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe ...